News
FDA cites 'significant concerns' with ADC lymphoma trial
ADC Therapeutics' chances of upgrading its accelerated approval for DLBCL therapy Zynlonta to a full approval have taken a knock.
News
Manufacturing issues mar ITM's radiopharma filing, says FDA
ITM's first attempt to score FDA approval for one of its radiopharma therapies has been knocked back by the agency.
News
Ex-BioNTech execs launch 'AI-native' cancer company
Two senior executives formerly at BioNTech have launched a new biotech, Bios Life, that they call "an AI-native cancer surveillance company."
News
Sobi adds rare lymphoma drug with $580m Innate tie-up
Sobi chief executive Guido Oelkers is preparing his exit, but is still cutting deals, licensing a lymphoma drug from Innate for up to $580m.
News
Quartet of biotechs join Nasdaq after stellar IPOs
Braveheart Bio, Latigo Biotherapeutics, Attovia Therapeutics, and BlossomHill Therapeutics have finalised their Nasdaq listings, raising over $1.2bn.
News
Views & Analysis
Deep Dive
Editor's Picks
Editor's Picks
